View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 11, 2021updated 11 Jul 2022 2:22pm

Pacific Cancer Care to use Deep Lens’ AI solutions for clinical trials

Deep Lens’ VIPER solution can aid in automating the selection of eligible subjects during diagnosis and match them to trials. 

Pacific Cancer Care will use Deep Lens ’ artificial intelligence (AI)-based solutions to streamline its clinical trial matching and expedite enrolment for cancer patients after the companies entered a partnership.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The collaboration will extend Pacific Cancer Care ’s current clinical trial offering to people by precisely and efficiently detecting eligible patients for trials, boosting communications between patient care groups and taking more trials to the practice.

According to estimates, more than 15,000 cancer trials are actively enrolling subjects, but less than one in 30 patients take part in a trial.

Reduced trial site resources make it time-consuming to detect eligible subjects, especially when the complexity of the trial protocols rises.

Deep Lens ’ AI solution VIPER automates the process of detecting potentially eligible subjects during diagnosis and matches them to related trials and offers support to care teams.

By pre-screening all patients from EMR (OncoEMR) of Pacific Cancer Care , VIPER can merge molecular data feeds from Caris Life Sciences , Foundation Medicine and Guardant Health , and all pathology feeds to automatically find qualified subjects for trials.

The pre-screening and trial matching solution of Deep Lens is offered at zero cost to oncology practices.

Pacific Cancer Care oncologist Zach Koontz said: “Clinical trials are not only critical to the advancement of new therapeutic options for cancer, but they present a unique opportunity for patients to access novel treatments well in advance of their commercialization, some of which may help positively impact the state of their disease.

“We are excited to partner with Deep Lens to broaden our clinical research program through an increased number of trials that we can offer onsite and by expediting the time we can get patients into these trials.”

In June this year, the Center for Cancer and Blood Disorders (The CenterTX) in the US announced plans to deploy Deep Lens ’ AI-based clinical trial screening and enrolment solution VIPER.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena